[HTML][HTML] A novel player in inflammation and cancer: The deubiquitinase CYLD controls HCC development
J Gautheron, T Luedde - Journal of hepatology, 2012 - journal-of-hepatology.eu
During the past decades, hepatocellular carcinoma (HCC) became a major health burden
and currently represents the third leading cause of cancer-related mortality worldwide [1].
While a continuous decline in cirrhosis-related mortality was observed over the past
decades, mortality rates for HCC increased until the end of the last millennium. In fact, the
incidence of HCC still nearly equals its mortality rate [2]. The introduction of the multi tyrosine
kinase inhibitor sorafenib represented a major breakthrough for the therapy of HCC [3] …
and currently represents the third leading cause of cancer-related mortality worldwide [1].
While a continuous decline in cirrhosis-related mortality was observed over the past
decades, mortality rates for HCC increased until the end of the last millennium. In fact, the
incidence of HCC still nearly equals its mortality rate [2]. The introduction of the multi tyrosine
kinase inhibitor sorafenib represented a major breakthrough for the therapy of HCC [3] …